Arrowhead’s Redemplo secures Australian TGA approval for FCS therapy

Arrowhead Pharmaceuticals has received approval from the Australian TGA for Redemplo to treat familial chylomicronemia syndrome. The approval marks an expansion of access for a genetic disorder estimated to affect one to 13 people per million worldwide. The TGA approval is backed by Phase III PALISADE data from 39 global sites, including five in Australia. Credit: Sai Thaw Kyar/Shutterstock.com. Arrowhead Pharmaceuticals has received approval from the Australian Therapeutic Goods Administration (TGA) for Redemplo (plozasiran) to treat familial chylomicronemia syndrome (FCS). The therapy is approved as an add-on to diet, specifically for adults with FCS whose triglyceride levels remain high despite…

Source: Pharmaceutical Technology